Main page content

Displaying results 21 - 30 of 72
Publication ID: PEP22-08-03-008
Published:
Este póster de 18x24 pulgadas ayuda a publicitar el nuevo 988 Línea de Prevención del Suicido y Crisis y proporciona acceso a este recurso que salva vidas. Este póster está diseñado para ser colocado en escuelas, centros comunitarios, oficinas de asesoramiento, clínicas y otros lugares donde se reúnen las personas.
Publication ID: PEP22-07-03-001
Published:

An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

Publication ID: PEP21-05-00-001
Published:

This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.

Publication ID: PEP21-02-01-004
Published:

This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.

Publication ID: PEP21-06-02-002
Published:

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

Publication ID: PEP21-02-01-003
Published:

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

Publication ID: PEP21-02-01-002
Published:

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

Publication ID: PEP21-06-02-001
Published:

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

Publication ID: PEP21-PL-Guide-6
Published:

This guide helps health care providers, systems, and communities support recovery from substance use disorders via employment mechanisms. It describes relevant research, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers resources.

Publication ID: PEP20-03-10-001
Published:

This guide highlights steps taken by the Frostburg State University community to reduce underage and high-risk drinking among the student population and discusses how these strategies were implemented.

Displaying 21 - 30 out of 72